1 study found for:    21514250 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Recruiting Safety Study of TPI-287 to Treat CBS and PSP
Conditions: Primary Four Repeat Tauopathies (4RT);   Corticobasal Syndrome (CBS);   Progressive Supranuclear Palsy (PSP)
Interventions: Drug: TPI 287 2 mg/m2;   Drug: TPI-287 20 mg/m2;   Drug: Placebo;   Drug: TPI-287 6.3 mg/m2

Indicates status has not been verified in more than two years